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Introduction
More than one million percutaneous coronary in-
terventions are carried out each year worldwide1 in
patients with acute coronary syndrome or medication-
refractory symptomatic coronary artery disease. The
net benefits of percutaneous coronary interventions
are, however, significantly diminished by the occur-
rence of restenosis, the rates of which are estimated to
be up to 40% 6 months post-balloon angioplasty or
20% post-stenting2,3. Several agents, such as heparin,
angiotensin-converting enzyme inhibitors, calcium–
calmodulin antagonists and growth factor antagonists,
have been used and demonstrated to reduce resteno-
sis in animal studies4,5. Human trials, however, have
generally failed to repeat their efficacy6, reflecting the
fact that targeting only a single mitogenic factor or
pathway is not sufficient for treating a multifactorial
disease, such as restenosis. Given that neointimal
thickening is the mainstay of pathologic findings in
restenotic lesions2,3,7,8 and that cell cycle activation is the
final and the essential step to enable neointimal cells
to proliferate, targeting cell cycle regulators could be 
a promising therapeutic strategy in the prevention of
restenosis5,9. The recent encouraging reports10,11 show-
ing that drug-eluting stents coated with rapamycin
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(sirolimus) or paclitaxel, which act on cell cycle regula-
tion and were originally used in cancer treatment12–14,
were able to successfully reduce the 6-month resteno-
sis rates to 0%, further supporting the notion that 
the cell cycle is an ideal and feasible target for the
treatment of restenosis. However, the drug-eluting
stent also has its Achilles heel, i.e., late stent throm-
bosis15,16, which is thought to result from delayed re-
endothelialization17,18. A better understanding of cell
cycle regulation in different vascular cells, such as vas-
cular smooth muscle cells (VSMC) and endothelial cells
(EC), would further refine the target and allow investi-
gation of differential cell cycle regulation in the distinct
vascular cells.
Cell Cycle Progression
The normal cell cycle (Figure 1) is regulated by a fam-
ily of serine/threonine protein kinases, called cyclin-
dependent kinases (CDKs)19, which require association
with distinct regulatory subunits, namely cyclins20, to
form active holoenzymes for progression through specific
points of the cell cycle. Among all CDK–cyclin complexes,
the activities of CDK2, which forms the CDK2–cyclin E
complex, are especially important for cells to progress
through the G1 restriction point21 (Figure 1). To tune the
cell cycle progression in a more sophisticated way, the
activities of cyclin–CDK complexes are further regu-
lated by CDK phosphorylation22 and the levels of CDK
inhibitors (CDKIs)22–25.
p27Kip1 is probably the most important and well-
studied CDKI, and was first recognized as a CDKI because
of its ability to inhibit the activity of cyclin E–CDK2 and
cyclin A–CDK2 complexes in cells arrested in G1 by trans-
forming growth factor-β26,27. p27Kip1 is expressed at high
levels when the cells are in the quiescent (G0) state,
which can be induced either by serum starvation28 or by
loss of cell adhesion29, and is rapidly downregulated
when cells enter G1. Because the activities of CDK227
and CDK130 are both inhibited by p27Kip1, the down-
regulation of p27Kip1 is crucial for both the G1/S transi-
tion (or progression through the G1 restriction point;
Figure 1)31 and G2/M progression30,32. Although the
protein levels of p27Kip1 oscillate during the cell cycle,
p27Kip1 messenger RNA (mRNA) levels basically do not
change during an unperturbed cell cycle33,34; in other
words, its protein levels are mainly regulated through
its degradation35.
What is Skp2?
The levels of many cell cycle effectors, such as p27Kip1,
are regulated by their degradation36–38, which is medi-
ated by a rapidly responsive and highly efficient mech-
anism called ubiquitin-mediated proteolysis39. Through
the action of ubiquitin ligase, the protein to be degraded
is first labeled with a chain of ubiquitins, a process call-
ed polyubiquitination. The labeled protein (i.e., poly-
ubiquitinated protein) is then recognized by the “waste
disposer” 26S proteasome for the subsequent break-
down40,41 (Figure 2).
Skp1–Cul1–F-box (SCF) ubiquitin ligase (Figure 2) is
one of the major ubiquitin ligases that regulate cell
cycle progression, and its highly variable F-box subunit
determines the substrate specificity40,43. S-phase kinase-
associated protein-2 (Skp2) is an F-box subunit of SCF
ubiquitin ligase (Figure 2), responsible for the poly-
ubiquitination and subsequent degradation of many cell
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Figure 1. Overview of the cell cycle. Resting vascular smooth
muscle cell remain in a quiescent state (G0). With adequate
mitogenic stimulation, activated cells enter the first gap peri-
od (G1), during which the factors necessary for DNA replica-
tion for the subsequent synthetic phase (S) are assembled.
After DNA replication is completed, the cells enter the second
gap period (G2) to prepare for subsequent mitosis (M). The
restriction point (R) is at the G1/S interphase. Before this
point, the cell cycle is growth factor-dependent, and with-
drawal of growth factor forces cells back to the quiescent state.
Beyond this point, however, the cells acquire growth-factor
independence and become committed to enter the S phase.
The cell cycle is driven by a group of cyclin-dependent kinases
(CDKs), the activities of which rely on the association of their
distinct regulatory subunits, i.e., cyclins, such as cyclin A (A),
cyclin B (B) and so forth, to form CDK–cyclin complexes.
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cycle regulators, including many CDKIs, e.g., p27Kip1 44,45,
p21Cip1 46,47 and p57Kip2 48, free cyclin E49, forkhead
transcription factor FOXO150, mitogen-activated pro-
tein kinase (MAPK) phosphatase-151, etc. Although Skp2
is able to target multiple cell cycle proteins, p27Kip1 is
thought to be the most important substrate of Skp2,
based on the observation that p27Kip1 accumulates in
Skp2-deficient cells31,49, and that the phenotypic and
histologic abnormalities of Skp2-deficient mice, such
as small body and organ sizes, nuclear enlargement,
polyploidy as well as centrosome overduplication, can
be almost completely rescued in Skp2/p27Kip1 doubly-
deficient mice30,31.
Skp2 and Oncogenesis
Knowing that Skp2 is responsible for degradation of
several CDKIs, especially p27Kip1, we are not surprised
that Skp2 has been deemed an oncogene52–54, and its
overexpression, along with the related p27Kip1 deregu-
lation, has become the indicators of cancer progres-
sion and poor disease prognosis55–64. Consistent with
the clinical observations, cancer cells have been found
to constitutively express Skp2 and proliferate when
placed in suspension54, while non-cancer cells expressed
high levels of p27Kip1 and remained in a quiescent
state65. Furthermore, Shim et al. also have demon-
strated that transgenic mice with Skp2 exclusively
expressed in the prostate gland could exhibit a low-
grade prostate carcinoma66. Taken together, all lines
of evidence point to the fact that Skp2 plays a crucial
role in the regulation of cell proliferation and, thus, in
cancer progression.
Skp2 and Vascular Restenosis
VSMC proliferation contributes significantly to the devel-
opment of post-angioplasty or in-stent restenosis3,8,67,68.
Although the role of Skp2 in cancer cell proliferation
has been well recognized, its role in the regulation of
VSMC proliferation is less well understood. We were
the first to elucidate how Skp2 regulates VSMC prolifer-
ation in vitro and in vivo69–71.
VSMCs in healthy vessels are maintained in a quies-
cent state72, even in the presence of growth factors73.
Being isolated from a vessel or when the vessels are
injured, VSMCs regain the ability to proliferate and be-
come responsive to growth factor stimulation73,74. We
have previously demonstrated that a high p27Kip1 level
is the major reason why VSMC in the uninjured vessel
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Figure 2. Skp2-mediated polyubiquitination and proteolysis. Skp2 is an F-box subunit of SCFSkp2 ubiquitin ligase. The SCF
ubiquitin ligase is composed of three invariable subunits (scaffold), i.e., Skp1, Cul1 and Rbx, and a highly variable subunit, 
F-box protein, which is responsible for substrate recognition and thus determines the specificity of different SCF ubiquitin 
ligases. When Skp2 is in position, the Skp2-binding substrates, such as p27Kip1, p21Cip1 or some other cell cycle regulators, 
are “labeled” with multiple ubiquitins (polyubiquitinated), and the labeled proteins are subsequently degraded by the 26S
proteasome. The released ubiquitins are then recycled for the next proteolytic process. The structure of the SCFSkp2 ubiquitin
ligase is reproduced here with permission from Zheng et al.42.
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can be kept quiescent even in the presence of growth
factors73, and subsequently found that an extremely
low level of Skp2 expression accounts for the abun-
dant p27Kip1 in the intact vessel69. In contrast, Skp2 ex-
pression is significantly upregulated and, thus, p27Kip1
downregulated when the cultured VSMCs start to pro-
liferate after serum stimulation69,71 or when the carotid
VSMCs and neointimal cells are proliferating after bal-
loon injury71,75. Importantly, the kinetics of Skp2
expression perfectly mirrors that of medial and neoin-
timal cell proliferation after balloon injury, indicating
that Skp2 expression is closely related to VSMC pro-
liferation, both in vitro and in vivo. Moreover, reports
showing that adenovirus-mediated Skp2 expression is
able to enhance VSMC S-phase entry even in the unin-
jured rat aorta69, and that silencing Skp2 expression by
Skp2 short interfering RNA in cultured VSMC reduces
the S-phase entry71, further supporting the notion that
Skp2 expression is essential for VSMC proliferation.
More importantly, we demonstrated that adenovirus-
mediated Skp2 expression significantly enhanced
neointimal thickening after filament-induced endo-
thelial denudation in rat carotid artery76 and that
neointimal formation was significantly diminished
after carotid ligation in Skp2-deficient mice as com-
pared with the wild-type mice77. Taken together, the
currently available evidence strongly suggests that
Skp2 regulates VSMC proliferation both in vitro and 
in vivo and thus could play a crucial role in vascular
restenosis.
Skp2 as a Common Final Pathway for 
VSMC Proliferation
Although a myriad of factors regulate VSMC prolifera-
tion, cell cycle regulation is the final common pathway
for those factors to exert their influence on cell prolif-
eration5. It would be very interesting to know if Skp2 is
one of the common pathways through which the extra-
cellular factors regulate VSMC proliferation.
Proliferation of mammalian cells, including VSMCs,
is strictly regulated by the surrounding environmental
factors. Both growth factor and extracellular matrix (ECM)
are indispensable for cell cycle progression, and loss of
either growth factor stimulation or ECM attachment
generally results in G1 arrest28,78, or even apoptosis in
some susceptible cells79. Indeed, we have clearly shown
that growth factors significantly enhance Skp2 mRNA
and protein expression in VSMCs71, and that inhibition
of growth factor-related signaling, such as extracellular
signal-related protein kinase, p38 MAPK and c-Jun 
N-terminal kinase, results in a reduction in VSMC Skp2
expression80. Furthermore, it has been demonstrated
that VSMCs lose their Skp2 expression when deprived
of ECM contact, and the distinct matrix attachments
have resulted in different amounts of Skp2 expression,
which perfectly mirrors the different effects of matrices
on VSMC proliferation69. Focal adhesion kinase (FAK)
signaling has been shown to be, at least partially,
involved in this process69.
Although positive regulators, such as growth fac-
tors and ECMs, are shown to positively regulate VSMC
proliferation through the upregulation of Skp2, it
would be of interest to know whether negative reg-
ulators, such as an intact endothelium, negatively reg-
ulate Skp2 expression in VSMC. An intact endothelium
is able to inhibit VSMC proliferation81,82, at least in
part, through an increase in prostacyclin83,84 and nitric
oxide84,85, which in turn increase intracellular levels of
cyclic nucleotides (cyclic adenosine monophosphate
[cAMP] and cyclic guanosine monophosphate [cGMP],
respectively)83,84,86. Indeed, cAMP analogues and cAMP-
elevating agents strongly inhibit Skp2 expression in
VSMC both in vitro and in vivo, through a decrease in
mRNA expression and an increase in protein break-
down71. Importantly, adenovirus-mediated ectopic Skp2
expression is found to significantly rescue cell prolifer-
ation in forskolin-(an adenylate cyclase activator)
treated VSMC71. cGMP analogues also significantly in-
hibit VSMC proliferation, though not as strongly as cAMP
analogues71. Collectively, both positive growth signals,
such as growth factors or ECMs, and negative growth
signals, such as cyclic nucleotides, affect VSMC prolif-
eration through the regulation of Skp2 expression.
Do these factors have a common downstream sig-
nal to Skp2? We incidentally found that the extent of
cyclic nucleotide-induced cell shape change (depicted
as “stellate” or “neuron-like” cells in the literature87) was
proportional to the inhibitory effects of cyclic nucle-
otides on Skp2 expression, implying that the signaling
pathway regulating cell shape change could be identi-
cal to that regulating Skp2 expression. Indeed, Rac1, a
member of the Rho GTPase subfamily which belongs
to the small G protein superfamily and is known to be
crucial for the maintenance of cell shape88, has been
demonstrated to be an important mediator upstream
of Skp289. This fact is supported by the evidence showing
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that the inhibition of Rac1 signaling by the expression of
dominant-negative Rac1 mutant induces the same cell
shape changes and reduces Skp2 expression in VSMC.
On the other hand, the expression of constitutively
active Rac1 mutant is able to prevent diminution of Skp2
and reverse the cell shape changes induced by cyclic
nucleotides89. Furthermore, vascular injury has also been
demonstrated to enhance Rac1 signaling as well as Skp2
expression, and, importantly, blocking Rac1 signaling
by the expression of dominant-negative Rac1 mutant
is able to reduce Skp2 upregulation and the final neoin-
timal thickening89. Growth factors, ECM attachment and
cyclic nucleotides are all able to affect the pathways
regulating Rac1 activity, and this integrated Rac1 signal-
ing can determine the final levels of Skp2 expression
and thus control VSMC proliferation (Figure 3)80.
Skp2 in Other Cells Contributing to 
Vascular Pathogenesis
Apart from VSMC, Skp2 has also been found to regulate
the proliferation of other cells, which may contribute
to vascular pathogenesis. For example, obesity is a risk
factor for the occurrence of cardiovascular events; Skp2
has been shown to control adipocyte proliferation
during the development of obesity, and Skp2-deficient
mice are less prone to diet-induced obesity and insulin
resistance90. EC proliferation, in contrast to VSMC pro-
liferation, contributes to re-endothelialization after vas-
cular injury and thus benefits vascular repair. Bryant
et al.91 clearly showed that growth factors and ECM
adhesion-related EC proliferation is mediated by the
FAK-Skp2-p27Kip1 axis, which is similar to the control
of VSMC proliferation69.
Interestingly, although cAMP strongly inhibits Skp2
expression and VSMC proliferation, it has not been
shown to significantly inhibit EC proliferation83 and Skp2
expression in human aortic EC (Wu YJ, unpublished data,
2008). Instead, there is even evidence showing that
cAMP signaling promotes EC proliferation92–94. The
detailed mechanism of how cAMP signaling induces
differential growth and Skp2 regulation between EC
and VSMC is now under investigation, and further elu-
cidation of this mechanism may provide invaluable
information for the future development of a better
treatment regime for vascular restenosis.
Conclusion
The Rac1-Skp2-p27Kip1 signaling axis plays an impor-
tant role in the regulation of VSMC proliferation.
Although many factors affect VSMC proliferation, the
currently available evidence suggests that this axis
may act as a common final pathway in VSMC to regu-
late cell cycle progression. Therefore, the Rac1-Skp2-
p27Kip1 axis could be a promising target for the
treatment of vascular restenosis. Furthermore, the fact
that cAMP signaling regulates VSMC and EC prolifera-
tion distinctly implies that there could be a differential
regulation of the Rac1-Skp2-p27Kip1 axis in different
vascular cells. Further elucidation of this differential
regulation may provide a new target for the develop-
ment of more ideal drug-eluting stents, which are able
to strongly inhibit neointimal thickening but without
delayed or enhanced endothelial regrowth.
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Figure 3. The Rac1-Skp2-p27Kip1 signaling axis. Both positive
regulators (growth factors or extracellular matrices [ECMs])
and negative regulators (cyclic nucleotides) of vascular smooth
muscle cell proliferation are able to upregulate and down-
regulate, respectively, the activity of Rac1, which is crucial
for actin polymerization and thus maintaining a proper cell
shape. On the other hand, Rac1 also upregulates Skp2 expres-
sion, which in turn increases the degradation of p27Kip1,
releases CDK2 from the inhibition, and thereby allows cells
to progress through the G1/S transition. Actually, Rac1 has
recently been proven to regulate Skp2 expression, at least in
part, through actin polymerization89.
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